DHR Stock Recent News

Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.

Danaher (DHR) is set to benefit from strength across its businesses, acquired assets and shareholder-friendly policies.

Healthcare's impact on the economy cannot be overstated. According to the American Medical Association, the U.S. spends more than $4 trillion a year on healthcare, which works out to nearly $13,000 per person.

In the closing of the recent trading day, Danaher (DHR) stood at $244.28, denoting a +0.98% change from the preceding trading day.

Danaher (DHR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In the closing of the recent trading day, Danaher (DHR) stood at $245.94, denoting a -0.75% change from the preceding trading day.

Danaher (DHR) reachead $248.77 at the closing of the latest trading day, reflecting a +0.12% change compared to its last close.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Danaher Corporation is a leading player in the life science industry, with strong financial performance despite many spin-offs. The healthcare industry is facing challenges due to weak funding and high vacancy rates in lab spaces, but there are signs of a turnaround. While the valuation is rising, I believe investors can still take advantage of the momentarily weak market opportunity.